Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 27, 2026 08:00 ET | Source: Cytokinetics, Incorporated

Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

“On Track with HCM” Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone’s Father, Willie McLaughlin SOUTH SAN FRANCISCO,...
January 27, 2026 08:00 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN

Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE...
January 27, 2026 08:00 ET | Source: Teva Pharmaceutical Industries Ltd

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’

Actor and comedian, Will Forte, opens up about his brother-in-law's journey with Huntington’s disease (HD) and chorea through Teva’s Honestly HD programHD is a rare, progressive genetic disorder often...
January 27, 2026 07:30 ET | Source: BriaCell Therapeutics Corp.

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populationsNo...
January 27, 2026 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy), to be presented at...
January 27, 2026 05:00 ET | Source: StarkAge Therapeutics

StarkAge Therapeutics Announces Research Collaboration with Gustave Roussy to Advance Senolytic Therapies in Digestive Cancers

The collaboration will inform patient selection for treatment with STX-1, a first-in-class senolytic ADC directed against DPP4/CD26.
January 27, 2026 04:12 ET | Source: Precision Health Holdings

Precision Health Holdings Appoints Emma Rooth as Chief Executive Officer of PCCA UK

PRUDHOE, UK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Emma Rooth has been appointed Chief Executive Officer of PCCA UK by Precision Health Holdings, the strategic holding company of PCCA UK and other...
January 27, 2026 04:00 ET | Source: Augere Medical AS

Distractions Down, Confidence Up: New AI Colonoscopy Software Delivers More Transparent Polyp Detection

OSLO, Norway, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Augere Medical (“Augere”), a European pioneer in AI-assisted colonoscopy, today announced the commercial release of its next-generation software...
January 26, 2026 18:45 ET | Source: Mesoblast Limited

Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment

NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on use of...
January 26, 2026 16:50 ET | Source: Birger Nispel International Academy

German-Japanese Medical Tech Innovation Celebrated by Birger Nispel International Academy at MEDICA

Bochum, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Bochum Expert Nispel Presents Medical Technology Award to Japanese Companies for the First Time At the world’s largest medical technology trade fair,...